Database on monoclonal antibodies to Cytokeratins

Upasani, Ojaswini S; Vaidya, Milind M.; Bhisey, A.N.

doi:10.1016/j.oraloncology.2003.08.022

Cited by 18 publications

(9 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Archival material was used in the present study and therefore its possible that antigenicity may have been lost over time, making immunostaining with certain antibodies less effective. 3 Vaidya et al 8 demonstrated a reduction in CK 5 expression in cases of mild and moderate oral dysplasia, indicating an increased potential for progression to malignancy. In the present study, cases of dysplasia that showed no AE1/AE3 staining in the basal layer may be lesions that are more likely to progress to malignancy.…”

Section: Discussionmentioning

confidence: 99%

“…7 All our three respective cases showed moderate chronic inflammatory cell infiltrate. Ogden et al and Nie et al [8][9][10] showed suprabasal expression of CK 19 supportive of a field change and can be used as a candidate marker for diagnosis of oral precancerous lesions and determination of the differentiation level of oral squamous cell carcinoma. So, AE1/AE3 antibody proved helpful in detecting malignant changes in clinically normal appearing mucosa (mirror image biopsy).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Histologic and immunohistochemical evaluation of mirror image biopsies in oral squamous cell carcinoma

Gupta

Ramani

2016

Journal of Oral Biology and Craniofacial Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Histologic and immunohistochemical evaluation of mirror image biopsies in oral squamous cell carcinoma

Gupta

Ramani

2016

Journal of Oral Biology and Craniofacial Research

View full text Add to dashboard Cite

“…Keratin and keratin‐associated genes encode intermediate filament proteins, are expressed specifically in epithelial cells and their appendages and are currently used as markers for various malignancies and other diseases (Upasani et al . ). One study highlighted a synergistic effect of alcohol consumption and BMI on serum concentrations of keratin‐18 (Gonzalez‐Quintela et al .…”

Section: Discussionmentioning

confidence: 97%

Genome‐wide association study of body mass index in subjects with alcohol dependence

et al. 2015

View full text Add to dashboard Cite

Outcomes related to disordered metabolism are common in alcohol dependence (AD). To investigate alterations in the regulation of body mass that occur in the context of AD, we performed a GWAS of BMI in African-Americans (AAs) and European-Americans (EAs) with AD. Subjects were recruited for genetic studies of alcohol or drug dependence, and evaluated using the Semi-Structured Assessment for Drug Dependence and Alcoholism. We investigated a total of 2,587 AAs and 2,959 EAs with DSM-IV AD diagnosis. In the stage-1 sample (N=4,137), we observed three genome-wide significant (GWS) SNP associations, rs200889048 (p=8.98*10−12) and rs12490016 (p=1.44*10−8) in EAs, and rs1630623 (p=5.14*10−9) in AAs and EAs meta-analyzed. In the stage-2 sample (N=1,409), we replicated 278, 253, and 168 of the stage-1 suggestive loci (p<5*10−4) in AAs, EAs, and AAs and EAs meta-analyzed, respectively. A meta-analysis of stage-1 and stage-2 samples (N=5,546) identified two additional GWS signals: rs28562191 in EAs (p=4.46*10−8) and rs56950471 in AAs (p=1.57*10−9). Three of the GWS loci identified (rs200889048, rs12490016, rs1630623) were not previously reported by GWAS of BMI in the general population and two of them raise interesting hypotheses: rs12490016 – a regulatory variant located within LINC00880, where there are other GWAS-identified variants associated with birth size, adiposity in newborns, and bulimia symptoms which also interact with social stress in relation to birth size; rs1630623 – a regulatory variant related to ALDH1A1, a gene involved in alcohol metabolism and adipocyte plasticity. These loci offer molecular insights regarding the regulatory mechanisms of body mass in the context of AD.

show abstract

“…Cytokeratins are being used extensively for tumor diagnosis in various types of malignancy [23]. Cytokeratins expressed by primary tumor cells [24] also remain present in invasive and metastatic cells, which additionally makes them good markers for local invasions and distant metastases [25].…”

Section: Discussionmentioning

confidence: 99%

Immunonanoparticles − an effective tool to impair harmful proteolysis in invasive breast tumor cells

et al. 2007

View full text Add to dashboard Cite

Cysteine cathepsins, an important group of lysosomal proteolytic enzymes [1,2], have been implicated in a number of steps in tumor progression, including processes of cell transformation and differentiation, motility, adhesion, invasion, angiogenesis and metastasis [3,4]. In particular, high activity of cathepsin B has been identified as an important tumor promoting factor capable of degrading proteins of the basement membrane and extracellular matrix (ECM) and enhancing progression of malignant disease. It has been demonstrated that, besides the extracellular cathepsin B, its intracellular fraction is involved in degrading the ECM, which is internalized by tumor cells and exposed to lysosomes [5,6].We and others have demonstrated that inhibitors that are able to enter cells, and thus inactivate lysosomal cathepsin B, effectively reduce ECM degradation and consequently cell invasiveness [6]. However, the uptake by aggressive tumor cells of cathepsin B inhibitors, either small molecules, protein inhibitors or neutralizing monoclonal antibodies, is a rather slow process with very limited final efficacy. A strategy to speed up the uptake and to target the inhibitors to the lysosomes would be most desirable. Cathepsin B, however, possesses several functions with respect to physiological processes of normal cells, such as intracellular protein catabolism, pro-hormone processing and regulation of cytotoxic immunity [7][8][9] Breast cancer cells exhibit excessive proteolysis, which is responsible for extensive extracellular matrix degradation, invasion and metastasis. Besides other proteases, lysosomal cysteine protease cathepsin B has been implicated in these processes and the impairment of its intracellular activity was suggested to reduce harmful proteolysis and hence diminish progression of breast tumors. Here, we present an effective system composed of poly(d,llactide-coglycolide) nanoparticles, a specific anti-cytokeratin monoclonal IgG and cystatin, a potent protease inhibitor, that can neutralize the excessive intracellular proteolytic activity as well as invasive potential of breast tumor cells. The delivery system distinguishes between breast and other cells due to the monoclonal antibody specifically recognizing cytokeratines on the membrane of breast tumor cells. Bound nanoparticles are rapidly internalized by means of endocytosis releasing the inhibitor cargo within the lysosomes. This enables intracellular cathepsin B proteolytic activity to be inhibited, reducing the invasive and metastatic potential of tumor cells without affecting proteolytic functions in normal cells and processes. This approach may be applied for treatment of breast and other tumors in which intracellular proteolytic activity is a part of the process of malignant progression.Abbreviations ECM, extracellular matrix; EDC, 1-ethyl-3-(3-dimethylaminopopyl)carbodiimide hydrocloride; FITC, fluorescein isothiocyanate; PLGA, poly(D,L-lactide-coglycolide); TAA, tumor-associated antigen.

show abstract

Database on monoclonal antibodies to Cytokeratins

Cited by 18 publications

References 73 publications

Histologic and immunohistochemical evaluation of mirror image biopsies in oral squamous cell carcinoma

Histologic and immunohistochemical evaluation of mirror image biopsies in oral squamous cell carcinoma

Genome‐wide association study of body mass index in subjects with alcohol dependence

Immunonanoparticles − an effective tool to impair harmful proteolysis in invasive breast tumor cells

Contact Info

Product

Resources

About